4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
Science
; 375(6577): 161-167, 2022 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1648160
ABSTRACT
The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and older adults. We describe 4'-fluorouridine (4'-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with high selectivity index in cells and human airway epithelia organoids. Polymerase inhibition within in vitro RNA-dependent RNA polymerase assays established for RSV and SARS-CoV-2 revealed transcriptional stalling after incorporation. Once-daily oral treatment was highly efficacious at 5 milligrams per kilogram (mg/kg) in RSV-infected mice or 20 mg/kg in ferrets infected with different SARS-CoV-2 variants of concern, initiated 24 or 12 hours after infection, respectively. These properties define 4'-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2, and related RNA virus infections.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Nucleótidos de Uracilo
/
Virus Sincitial Respiratorio Humano
/
Infecciones por Virus Sincitial Respiratorio
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Tópicos:
Variantes
Límite:
Animales
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Science
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Science.abj5508
Similares
MEDLINE
...
LILACS
LIS